摘要
基因疗法是一种旨在将核酸递送至细胞以获得治疗效果的技术。原位基因治疗包括将基因产物施用到特定部位。与静脉内给药相比,它具有几个优点,例如减少潜在的副作用,需要较低的载体剂量,因此降低了成本。涉及原位基因转移的不同载体、给药途径和剂量已在动物模型和人体中进行了测试,原位基因治疗药物已获准上市。在这篇综述中,我们介绍了原位基因治疗在不同疾病中的应用,从单基因到多因素疾病,主要关注为关节内和眼内隔室设计的疗法,以及中枢神经系统 (CNS) 的基因疗法和肿瘤。基因疗法似乎终于成为一种可行的治疗方法。此处显示的临床方案数量的增长是显而易见的,在几项临床试验中观察到的积极结果表明,未来几年将有更多基于原位基因治疗的产品进入市场。
关键词: 原位基因治疗、关节内基因治疗、眼内基因治疗、脑内基因治疗、瘤内基因治疗、基因治疗临床试验。
图形摘要
Current Gene Therapy
Title:In Situ Gene Therapy
Volume: 21 Issue: 5
关键词: 原位基因治疗、关节内基因治疗、眼内基因治疗、脑内基因治疗、瘤内基因治疗、基因治疗临床试验。
摘要: Gene therapy is a technique that aims at the delivery of nucleic acids to cells, to obtain a therapeutic effect. In situ gene therapy consists of the administration of the gene product to a specific site. It possesses several advantages, such as the reduction in potential side effects, the need for a lower vector dose, and, as a consequence, reduced costs, compared to intravenous administration. Different vectors, administration routes and doses involving in situ gene transfer have been tested both in animal models and humans, with in situ gene therapy drugs already approved in the market. In this review, we present applications of in situ gene therapy for different diseases, ranging from monogenic to multifactorial diseases, focusing mainly on therapies designed for the intra-articular and intraocular compartments, as well as gene therapies for the central nervous system (CNS) and for tumors. Gene therapy finally seems to blossom as a viable therapeutic approach. The growth in the number of clinical protocols shown here is evident, and the positive outcomes observed in several clinical trials indicate that more products based on in situ gene therapy should reach the market in the next years.
Export Options
About this article
Cite this article as:
In Situ Gene Therapy, Current Gene Therapy 2021; 21 (5) . https://dx.doi.org/10.2174/1566523221666210504103323
DOI https://dx.doi.org/10.2174/1566523221666210504103323 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements